{"product_id":"zynex-swot-analysis","title":"Zynex SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eZynex demonstrates significant strengths in its proprietary technology and established market presence, but also faces potential threats from evolving reimbursement landscapes and competitive pressures. Understanding these dynamics is crucial for strategic decision-making.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind Zynex's strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Focus on Non-Invasive Pain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex's strength lies in its dedicated focus on non-invasive pain management through electrotherapy devices and supplies. This specialization directly addresses a growing demand for alternatives to pharmaceutical interventions, particularly opioids, aligning with broader healthcare shifts toward less invasive solutions.\u003c\/p\u003e\n\u003cp\u003eThe company's commitment to this niche positions it well within the expanding market for chronic pain management. For instance, the global pain management market was valued at approximately $87.5 billion in 2023 and is projected to reach $133.8 billion by 2030, with non-invasive methods playing a significant role.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsistent Order Growth and Revenue Performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex has shown impressive resilience with consistent order growth, seeing a 16% year-over-year increase in fiscal year 2024. This strong demand translated into a 4% rise in net revenue, reaching $192.4 million for the same period.\u003c\/p\u003e\n\u003cp\u003eWhile there were some ups and downs quarter-to-quarter, the overarching trajectory clearly indicates robust customer interest in Zynex's product offerings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Gross Profit Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex consistently demonstrates impressive gross profit margins, a testament to its effective operational strategies. For the entirety of 2024, the company achieved a gross profit margin of 80%, and in the fourth quarter of 2024, this figure stood at a strong 78%.\u003c\/p\u003e\n\u003cp\u003eThese high margins, primarily driven by its device sales and recurring supply revenue, signify Zynex's ability to control its cost of goods sold efficiently. This financial strength provides a solid base for overall profitability, offering a significant advantage in managing other operational expenses and investing in future growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Innovation and FDA Clearances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZynex demonstrates a strong commitment to product innovation, a key strength that fuels its growth. The company secured FDA clearance for its new TensWave device in 2024, marking a significant advancement in its pain management offerings.  Furthermore, Zynex is actively pursuing FDA submission for its NiCO laser pulse oximeter, signaling continued development in monitoring technology.\u003c\/p\u003e\n\u003cp\u003eThese strategic product developments, including a pipeline of orthopedic and cold therapy products, are designed to expand Zynex's market reach and diversify its revenue streams. This proactive approach to integrating advanced technology into its product portfolio positions Zynex favorably in the competitive medical device landscape.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eTensWave FDA Clearance:\u003c\/strong\u003e Received in 2024, enhancing pain management solutions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNiCO Laser Pulse Oximeter:\u003c\/strong\u003e Undergoing FDA submission, expanding monitoring capabilities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePortfolio Expansion:\u003c\/strong\u003e Includes orthopedic and cold therapy products, broadening market appeal.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic VA Partnership and Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZynex’s strategic partnership with Veterans Affairs (VA) Medical Centers, initiated in December 2024, represents a significant strength for market expansion. This alliance grants Zynex access to an enormous patient base, encompassing over 9 million veterans across 171 medical centers. This broad reach positions the company to significantly increase sales of its non-opioid pain management solutions within the nation's largest integrated healthcare system.\u003c\/p\u003e\n\u003cp\u003eThe VA partnership is a pivotal driver for Zynex's growth, offering:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eUnprecedented Market Access:\u003c\/strong\u003e Direct engagement with over 9 million veterans, a demographic with a high prevalence of chronic pain conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eScalable Distribution:\u003c\/strong\u003e The 171 VA medical centers provide a substantial network for deploying Zynex’s pain management technologies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCredibility and Validation:\u003c\/strong\u003e Association with the VA lends significant credibility to Zynex’s product efficacy and safety profile.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Growth Potential:\u003c\/strong\u003e This collaboration is anticipated to be a major contributor to Zynex's revenue streams in the coming years, capitalizing on the VA's commitment to alternative pain management strategies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Strength: \u003cstrong\u003e80%\u003c\/strong\u003e Gross Margin, Revenue Up \u003cstrong\u003e4%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex's strong financial performance is a key strength, highlighted by its impressive gross profit margins. In 2024, the company achieved an 80% gross profit margin, demonstrating efficient cost management. This financial health is further supported by consistent revenue growth, with a 4% increase in net revenue to $192.4 million in fiscal year 2024, driven by strong demand for its pain management devices and supplies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eQ4 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue\u003c\/td\u003e\n\u003ctd\u003e$192.4 million\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin\u003c\/td\u003e\n\u003ctd\u003e80%\u003c\/td\u003e\n\u003ctd\u003e78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-over-Year Order Growth\u003c\/td\u003e\n\u003ctd\u003e16%\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Zynex’s internal and external business factors, identifying key strengths, weaknesses, opportunities, and threats to inform its market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a clear visual representation of Zynex's competitive advantages and potential challenges in the pain relief market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Decline in Net Income and Profitability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex has faced a significant downturn in its financial performance, marked by a substantial drop in net income. For the full year 2024, net income plummeted to $3.0 million, a stark contrast to the $9.7 million recorded in 2023, signifying a 69% reduction in profitability.\u003c\/p\u003e\n\u003cp\u003eThis weakening trend has unfortunately persisted into the first half of 2025. The company reported a net loss of ($10.4) million for the first quarter of 2025, followed by an even larger net loss of ($20.0) million in the second quarter of 2025, highlighting ongoing and considerable profitability challenges.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTemporary Tricare Payment Suspension\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA significant weakness for Zynex is the temporary suspension of payments from Tricare, a crucial payer that historically represented 20-25% of the company's annual revenue. This disruption has directly impacted Zynex's financial performance, leading to notable revenue shortfalls and a negative cash flow situation. The company's reliance on this payment stream highlights a vulnerability in its revenue diversification strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncreased General and Administrative Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA notable weakness for Zynex is the significant increase in its general and administrative (G\u0026amp;A) expenses. In fiscal year 2024, these costs climbed to $60.4 million, a substantial jump from $48.5 million reported in 2023. This escalation in overhead, even as sales and marketing expenditures saw a reduction, directly impacts the company's bottom line.\u003c\/p\u003e\n\u003cp\u003eThe rising G\u0026amp;A expenses, coupled with a downturn in net income, create a challenging financial scenario for Zynex. This trend suggests potential inefficiencies in operational management or increased costs associated with supporting the business infrastructure, thereby diminishing overall financial performance and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWorkforce Reductions and Sales Force Productivity Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZynex's decision to reduce its workforce by 15%, impacting primarily corporate departments, is projected to yield annual savings of roughly $35 million. This move, while financially prudent in the face of revenue uncertainties, could potentially strain operational capacity and negatively affect employee morale.  The company is simultaneously focusing on enhancing sales representative productivity to offset these impacts.\u003c\/p\u003e\n\u003cp\u003eThe workforce reduction, while a cost-saving measure, presents a significant challenge.  It can lead to increased workloads for remaining staff and a potential dip in overall productivity if not managed carefully.  Zynex's strategy to boost sales force efficiency is crucial for mitigating these risks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eWorkforce Reduction:\u003c\/strong\u003e A 15% staff cut, primarily in corporate, aims to save $35 million annually.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperational Impact:\u003c\/strong\u003e Such reductions can strain remaining staff and affect operational capacity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMorale Concerns:\u003c\/strong\u003e Workforce cuts can negatively impact employee morale and company culture.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Productivity Focus:\u003c\/strong\u003e Zynex is prioritizing efforts to increase the productivity of its sales representatives.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllegations of Oversupplying Scheme\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAllegations of an oversupplying scheme have cast a shadow over Zynex's operations, suggesting the company may have shipped more products to customers than were medically necessary or ordered. This practice raises serious questions about the integrity of their sales and billing procedures.\u003c\/p\u003e\n\u003cp\u003eIf these allegations are substantiated, the repercussions could be significant. Investor confidence might wane, potentially impacting Zynex's stock performance. Furthermore, relationships with insurers, who are responsible for reimbursement, could be strained, leading to payment delays or denials.\u003c\/p\u003e\n\u003cp\u003eThe potential for increased regulatory scrutiny is also a major concern. Investigations into such practices could result in fines, sanctions, or mandated changes to Zynex's business model, further disrupting their ability to operate and grow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eAllegations of shipping excess products\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eQuestions raised about sales and billing practices\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePotential negative impact on investor confidence\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRisk of strained insurer relationships and regulatory scrutiny\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue Plunge, Costs Soar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex's financial health is a significant concern, evidenced by a steep decline in net income for 2024, falling to $3.0 million from $9.7 million in 2023, a 69% decrease. This downward trend continued into early 2025 with substantial net losses reported in both the first and second quarters, totaling ($10.4) million and ($20.0) million respectively.\u003c\/p\u003e\n\u003cp\u003eThe temporary suspension of payments from Tricare, a key payer representing 20-25% of annual revenue, has severely impacted Zynex's cash flow and revenue generation. Compounding these issues, general and administrative expenses surged to $60.4 million in 2024, up from $48.5 million in 2023, indicating potential operational inefficiencies and increased overhead costs.\u003c\/p\u003e\n\u003cp\u003eThe company's recent 15% workforce reduction, while aimed at saving $35 million annually, poses risks to operational capacity and employee morale. Furthermore, allegations of an oversupplying scheme threaten investor confidence, insurer relationships, and could invite increased regulatory scrutiny, potentially leading to fines and operational disruptions.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eQ1 2025\u003c\/th\u003e\n\u003cth\u003eQ2 2025\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e$9.7 million\u003c\/td\u003e\n\u003ctd\u003e$3.0 million\u003c\/td\u003e\n\u003ctd\u003e($10.4) million\u003c\/td\u003e\n\u003ctd\u003e($20.0) million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTricare Revenue Share\u003c\/td\u003e\n\u003ctd\u003e20-25%\u003c\/td\u003e\n\u003ctd\u003eImpacted\u003c\/td\u003e\n\u003ctd\u003eImpacted\u003c\/td\u003e\n\u003ctd\u003eImpacted\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A Expenses\u003c\/td\u003e\n\u003ctd\u003e$48.5 million\u003c\/td\u003e\n\u003ctd\u003e$60.4 million\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Reduction\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eZynex SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview reflects the real document you'll receive—professional, structured, and ready to use. You'll gain a comprehensive understanding of Zynex's internal strengths and weaknesses, alongside external opportunities and threats. This detailed analysis will equip you with actionable insights for strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":55297255932252,"sku":"zynex-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/zynex-swot-analysis.png?v=1755791637","url":"https:\/\/pestel-analysis.com\/products\/zynex-swot-analysis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}